Pub Date : 2026-03-03DOI: 10.1016/s2213-2600(26)00050-0
{"title":"Innovation is needed to avoid closure of rural US hospitals","authors":"","doi":"10.1016/s2213-2600(26)00050-0","DOIUrl":"https://doi.org/10.1016/s2213-2600(26)00050-0","url":null,"abstract":"","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"90 1","pages":"187"},"PeriodicalIF":76.2,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147360564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-03DOI: 10.1016/s2213-2600(26)00058-5
Talha Burki
No Abstract
没有抽象的
{"title":"Asthma in India: myths, misdiagnosis, and high mortality","authors":"Talha Burki","doi":"10.1016/s2213-2600(26)00058-5","DOIUrl":"https://doi.org/10.1016/s2213-2600(26)00058-5","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"200 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147359573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-26DOI: 10.1016/s2213-2600(26)00005-6
Anne E Holland, Mariana Hoffman, Tamera J Corte, Daniel C Chambers, Graham Hepworth, Magnus P Ekström, Ian Glaspole, Nicole S Goh, Yet H Khor, Andrew J Palmer, Carly Barton, Ingrid Cox, Leona Dowman, Jonas Einarsson, Lisa Fuhrmeister, John A Mackintosh, Pernilla Neglén, Jyotika D Prasad, Jessica Bucciarelli, Simon Scherp, Christine F McDonald
Background
Ambulatory oxygen therapy can be used to treat exertional hypoxaemia during daily life activities in people with fibrotic interstitial lung disease (ILD). However, evidence for its efficacy is scarce. This trial aimed to compare the effects of ambulatory oxygen with ambulatory air on physical activity in daily life over 6 months in people with fibrotic ILD and isolated exertional hypoxaemia.
Methods
This multicentre, parallel-group, randomised, sham-controlled trial was done at seven hospital sites in Australia and Sweden. Eligible participants were aged ≥18 years with fibrotic ILD and isolated exertional hypoxaemia (ie, oxyhaemoglobin saturation [SpO2] ≤88% on 6-min walk test). Participants were randomly assigned (1:1) to receive ambulatory oxygen during daily activities delivered using a portable oxygen concentrator (Inogen One G3HF), or air delivered using a device identical in appearance, display, weight, and operation (sham). The primary outcome was change in physical activity (mean steps per day) at 3 months, measured using the StepWatch activity monitor in the intention-to-treat population. The trial is registered with ClinicalTrials.gov (NCT03737409) and is completed.
Findings
Between Aug 6, 2019, and Jan 10, 2024, 614 individuals were assessed for eligibility. 116 were randomly assigned to ambulatory oxygen (n=59) or ambulatory air (n=57). 79 (68%) of 116 participants were male and 37 (32%) were female. Mean age was 71 years (SD 10). There was no significant difference between ambulatory oxygen (–271 steps per day, 95% CI –702 to 161) and ambulatory air (64, –377 to 505) for change in mean steps per day at 3 months (–334, –803 to 134). There were no serious adverse events related to study treatments, and no difference between groups for the number or type of adverse events.
Interpretation
In people with fibrotic ILD and exertional hypoxaemia, ambulatory oxygen delivered using a portable concentrator did not provide benefits over ambulatory air for physical activity in daily life. Routine prescription of ambulatory oxygen using a portable oxygen concentrator for people with fibrotic ILD with isolated exertional hypoxaemia might not be indicated. These results reinforce the pressing need for innovation in portable oxygen devices to ensure effective oxygen delivery and acceptability to patients.
Funding
National Health and Medical Research Council (Australia) and Swedish Society of Medicine.
背景：动态氧疗可用于治疗纤维化间质性肺疾病（ILD）患者日常生活活动中的运动性低氧血症。然而，其有效性的证据很少。本试验旨在比较动态氧气和动态空气对纤维化ILD和孤立性运动性低氧血症患者6个月日常生活体力活动的影响。该多中心、平行组、随机、假对照试验在澳大利亚和瑞典的7家医院进行。符合条件的参与者年龄≥18岁，患有纤维化ILD和孤立性运动性低氧血症（即6分钟步行试验时血氧饱和度[SpO2]≤88%）。参与者被随机分配（1:1），在日常活动中使用便携式氧气浓缩器（Inogen One G3HF）接受动态氧气输送，或使用外观、显示、重量和操作相同的设备输送空气（假）。主要结局是3个月时身体活动（每天平均步数）的变化，使用StepWatch活动监测仪在意向治疗人群中测量。该试验已在ClinicalTrials.gov注册（NCT03737409）并已完成。在2019年8月6日至2024年1月10日期间，614人接受了资格评估。116例随机分为动态氧气组（n=59）和动态空气组（n=57）。116名参与者中有79名（68%）是男性，37名（32%）是女性。平均年龄71岁（SD 10）。3个月时，动态氧气（-271步/天，95% CI -702 ~ 161）和动态空气（64,-377 ~ 505）每天平均步数变化无显著差异（-334,-803 ~ 134）。没有与研究治疗相关的严重不良事件，两组之间不良事件的数量和类型没有差异。在纤维化ILD和运动性低氧血症患者中，使用便携式浓缩器输送的动态氧气在日常生活中并不比动态空气更有利于身体活动。对于纤维化ILD合并孤立性运动性低氧血症的患者，可能不需要使用便携式氧气浓缩器进行常规的动态氧气处方。这些结果加强了创新便携式氧气装置的迫切需要，以确保有效的氧气输送和患者的可接受性。资助国家卫生和医学研究委员会（澳大利亚）和瑞典医学会。
{"title":"Ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis (PFOX): a multicentre, randomised, sham-controlled trial","authors":"Anne E Holland, Mariana Hoffman, Tamera J Corte, Daniel C Chambers, Graham Hepworth, Magnus P Ekström, Ian Glaspole, Nicole S Goh, Yet H Khor, Andrew J Palmer, Carly Barton, Ingrid Cox, Leona Dowman, Jonas Einarsson, Lisa Fuhrmeister, John A Mackintosh, Pernilla Neglén, Jyotika D Prasad, Jessica Bucciarelli, Simon Scherp, Christine F McDonald","doi":"10.1016/s2213-2600(26)00005-6","DOIUrl":"https://doi.org/10.1016/s2213-2600(26)00005-6","url":null,"abstract":"<h3>Background</h3>Ambulatory oxygen therapy can be used to treat exertional hypoxaemia during daily life activities in people with fibrotic interstitial lung disease (ILD). However, evidence for its efficacy is scarce. This trial aimed to compare the effects of ambulatory oxygen with ambulatory air on physical activity in daily life over 6 months in people with fibrotic ILD and isolated exertional hypoxaemia.<h3>Methods</h3>This multicentre, parallel-group, randomised, sham-controlled trial was done at seven hospital sites in Australia and Sweden. Eligible participants were aged ≥18 years with fibrotic ILD and isolated exertional hypoxaemia (ie, oxyhaemoglobin saturation [SpO<sub>2</sub>] ≤88% on 6-min walk test). Participants were randomly assigned (1:1) to receive ambulatory oxygen during daily activities delivered using a portable oxygen concentrator (Inogen One G3HF), or air delivered using a device identical in appearance, display, weight, and operation (sham). The primary outcome was change in physical activity (mean steps per day) at 3 months, measured using the StepWatch activity monitor in the intention-to-treat population. The trial is registered with <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> (<span><span>NCT03737409</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>) and is completed.<h3>Findings</h3>Between Aug 6, 2019, and Jan 10, 2024, 614 individuals were assessed for eligibility. 116 were randomly assigned to ambulatory oxygen (n=59) or ambulatory air (n=57). 79 (68%) of 116 participants were male and 37 (32%) were female. Mean age was 71 years (SD 10). There was no significant difference between ambulatory oxygen (–271 steps per day, 95% CI –702 to 161) and ambulatory air (64, –377 to 505) for change in mean steps per day at 3 months (–334, –803 to 134). There were no serious adverse events related to study treatments, and no difference between groups for the number or type of adverse events.<h3>Interpretation</h3>In people with fibrotic ILD and exertional hypoxaemia, ambulatory oxygen delivered using a portable concentrator did not provide benefits over ambulatory air for physical activity in daily life. Routine prescription of ambulatory oxygen using a portable oxygen concentrator for people with fibrotic ILD with isolated exertional hypoxaemia might not be indicated. These results reinforce the pressing need for innovation in portable oxygen devices to ensure effective oxygen delivery and acceptability to patients.<h3>Funding</h3>National Health and Medical Research Council (Australia) and Swedish Society of Medicine.","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"71 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147292711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-25DOI: 10.1016/s2213-2600(25)00472-2
Deirdre Fitzgerald
No Abstract
没有抽象的
{"title":"Redefining the role of indwelling pleural catheters at thoracoscopy","authors":"Deirdre Fitzgerald","doi":"10.1016/s2213-2600(25)00472-2","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00472-2","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"10 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147292712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-25DOI: 10.1016/S2213-2600(25)00409-6
Alexandra Dipper, Anand Sundaralingam, Emma Hedley, Sharada Gudur, Janet Mills, Sandra Sowden, John P Corcoran, Cyrus Daneshvar, Chris Craig, Andrew J Moore, Alice Milne, Amelia Clive, Rahul Bhatnagar, Mark E Roberts, Thapas Nagarajan, Farheen Kutubudin, Helen Wassal, Moustafa Aboushehata, Sana Iftikhar, Mohammed Haris, Manjumol Abraham, Rajini Sudhir, Rakesh K Panchal, Duneesha de Fonseka, Eihab O Bedawi, Beenish Iqbal, Dinesh Addala, John Wrightson, Daniel Menzies, Svetlana Ratushnyak, Ramon Luengo-Fernandez, Robert F Miller, Paul White, Mohammed Munavvar, Najib M Rahman, Nick Maskell
<p><strong>Background: </strong>Patients with suspected malignant pleural effusions (MPE) are often in need of both a confirmatory diagnosis and symptom control. Therapeutic options include talc pleurodesis via chest drain, poudrage during medical thoracoscopy, or alternatively an indwelling pleural catheter (IPC). Combining the diagnostic and therapeutic efficacy of medical thoracoscopy and poudrage with the ambulatory benefits of an IPC has not been studied within a randomised controlled trial. The aim of the TACTIC trial was to determine whether this approach resulted in a reduced length of hospital stay and improvements in dyspnoea.</p><p><strong>Methods: </strong>This unblinded, phase 3, randomised controlled trial was undertaken in 11 UK hospitals. Patients with MPE and confirmed malignancy (during medical thoracoscopy or beforehand) received talc poudrage and were randomly assigned by a centralised web-based system to an IPC at the time of medical thoracoscopy or usual care (ie, medical thoracoscopy, poudrage, and admission with large bore tube). Co-primary outcomes were time in hospital (including initial admission for trial procedure and any subsequent readmissions over 4 weeks post procedure) and average breathlessness assessed with visual analogue scale dyspnoea scores, measuring severity of dyspnoea from 0 mm to 100 mm, over a 4-week period. All randomised patients in whom an outcome was available were included in the analysis on a modified intention-to-treat basis. TACTIC was registered with ISRCTN on Aug 8, 2021 (ISRCTN11058680).</p><p><strong>Findings: </strong>Participants were recruited from between Dec 15, 2021, and Jan 3, 2024. 124 participants were randomised: 62 to the intervention and 62 to standard care. Leading diagnoses were pleural mesothelioma (46%), lung cancer (28%), and breast cancer (10%). Co-primary outcome data were available for 102 patients for total length of hospital stay (52 in intervention group vs 50 in standard care group) and 108 patients for breathlessness (57 vs 51). Median time in hospital was 1 day (IQR 1-3, 95% CI 1-2) in the intervention group versus 2 days (IQR 1-3, 95% CI 1-2) in standard care group (p=0·26). Median visual analogue scale dyspnoea scores did not differ between groups: 14·0 mm (IQR 8·8-32·4) in the intervention group versus 19·6 mm (8·1-38·7) in standard care group (p=0·26). Participants in the intervention group required fewer additional invasive pleural procedures by 12 weeks (two [3%] of 60 vs 19 [34%] of 56, p<0·0001) Trial related adverse events rates were similar in both groups (46 [74%] of 62 vs 44 [71%] of 62, p=0·84). Three related serious adverse events were recorded, all occurring in the intervention group.</p><p><strong>Interpretation: </strong>The combination of medical thoracoscopy, poudrage, and IPC did not result in shorter hospital stay but was safe and resulted in similar dyspnoea control compared with standard care. For patients with symptomatic MPE undergoing med
背景：怀疑恶性胸腔积液（MPE）的患者往往需要确诊和症状控制。治疗方案包括通过胸腔引流进行滑石粉胸膜清除术，在医学胸腔镜检查期间进行灌注，或选择留置胸膜导管（IPC）。将医学胸腔镜和灌注的诊断和治疗效果与IPC的门诊益处相结合，尚未在随机对照试验中进行研究。战术试验的目的是确定这种方法是否能缩短住院时间和改善呼吸困难。方法：这项非盲法3期随机对照试验在英国11家医院进行。MPE和确诊恶性肿瘤的患者（在胸腔镜检查期间或之前）接受滑石粉粉末，并在进行胸腔镜检查或常规护理（即胸腔镜检查、粉末和大口径管入院）时由集中的网络系统随机分配到IPC。共同主要结局是住院时间（包括试验程序的首次入院和手术后4周内的任何后续再入院）和用视觉模拟呼吸困难评分评估的平均呼吸困难，测量4周内呼吸困难的严重程度，从0毫米到100毫米。所有可获得结果的随机患者均以改良的意向治疗基础纳入分析。战术已于2021年8月8日在ISRCTN注册（ISRCTN11058680）。研究结果：参与者是在2021年12月15日至2024年1月3日之间招募的。124名参与者被随机分配：62名干预组和62名标准治疗组。主要诊断为胸膜间皮瘤（46%）、肺癌（28%）和乳腺癌（10%）。102例患者的总住院时间（干预组52例，标准治疗组50例）和108例呼吸困难（57例，51例）的共同主要结局数据可用。干预组的中位住院时间为1天（IQR 1-3, 95% CI 1-2），而标准治疗组的中位住院时间为2天（IQR 1-3, 95% CI 1-2） （p= 0.26）。视觉模拟量表呼吸困难评分中位数在两组间无差异：干预组为14.0 mm (IQR为8.8 - 32.4)，标准治疗组为19.6 mm (8.1 - 38.7) （p= 0.26）。干预组的参与者在12周内需要更少的额外有创胸膜手术（60例中有2例[3%]vs 56例中有19例[34%]）。解释：医学胸腔镜、灌胃和IPC的结合并没有缩短住院时间，但是安全的，与标准护理相比，呼吸困难的控制效果相似。对于有症状的胸腔镜胸膜穿刺患者，如果他们优先考虑缩短住院时间或进一步进行有创胸膜手术，在灌注物的同时添加IPC可能有助于实现这一目标。资助：国家卫生研究所，病人利益研究。
{"title":"Medical thoracoscopy with talc poudrage and indwelling pleural catheter insertion versus medical thoracoscopy with talc poudrage alone for patients with symptomatic malignant pleural effusion (TACTIC): a randomised, controlled phase 3 trial.","authors":"Alexandra Dipper, Anand Sundaralingam, Emma Hedley, Sharada Gudur, Janet Mills, Sandra Sowden, John P Corcoran, Cyrus Daneshvar, Chris Craig, Andrew J Moore, Alice Milne, Amelia Clive, Rahul Bhatnagar, Mark E Roberts, Thapas Nagarajan, Farheen Kutubudin, Helen Wassal, Moustafa Aboushehata, Sana Iftikhar, Mohammed Haris, Manjumol Abraham, Rajini Sudhir, Rakesh K Panchal, Duneesha de Fonseka, Eihab O Bedawi, Beenish Iqbal, Dinesh Addala, John Wrightson, Daniel Menzies, Svetlana Ratushnyak, Ramon Luengo-Fernandez, Robert F Miller, Paul White, Mohammed Munavvar, Najib M Rahman, Nick Maskell","doi":"10.1016/S2213-2600(25)00409-6","DOIUrl":"https://doi.org/10.1016/S2213-2600(25)00409-6","url":null,"abstract":"<p><strong>Background: </strong>Patients with suspected malignant pleural effusions (MPE) are often in need of both a confirmatory diagnosis and symptom control. Therapeutic options include talc pleurodesis via chest drain, poudrage during medical thoracoscopy, or alternatively an indwelling pleural catheter (IPC). Combining the diagnostic and therapeutic efficacy of medical thoracoscopy and poudrage with the ambulatory benefits of an IPC has not been studied within a randomised controlled trial. The aim of the TACTIC trial was to determine whether this approach resulted in a reduced length of hospital stay and improvements in dyspnoea.</p><p><strong>Methods: </strong>This unblinded, phase 3, randomised controlled trial was undertaken in 11 UK hospitals. Patients with MPE and confirmed malignancy (during medical thoracoscopy or beforehand) received talc poudrage and were randomly assigned by a centralised web-based system to an IPC at the time of medical thoracoscopy or usual care (ie, medical thoracoscopy, poudrage, and admission with large bore tube). Co-primary outcomes were time in hospital (including initial admission for trial procedure and any subsequent readmissions over 4 weeks post procedure) and average breathlessness assessed with visual analogue scale dyspnoea scores, measuring severity of dyspnoea from 0 mm to 100 mm, over a 4-week period. All randomised patients in whom an outcome was available were included in the analysis on a modified intention-to-treat basis. TACTIC was registered with ISRCTN on Aug 8, 2021 (ISRCTN11058680).</p><p><strong>Findings: </strong>Participants were recruited from between Dec 15, 2021, and Jan 3, 2024. 124 participants were randomised: 62 to the intervention and 62 to standard care. Leading diagnoses were pleural mesothelioma (46%), lung cancer (28%), and breast cancer (10%). Co-primary outcome data were available for 102 patients for total length of hospital stay (52 in intervention group vs 50 in standard care group) and 108 patients for breathlessness (57 vs 51). Median time in hospital was 1 day (IQR 1-3, 95% CI 1-2) in the intervention group versus 2 days (IQR 1-3, 95% CI 1-2) in standard care group (p=0·26). Median visual analogue scale dyspnoea scores did not differ between groups: 14·0 mm (IQR 8·8-32·4) in the intervention group versus 19·6 mm (8·1-38·7) in standard care group (p=0·26). Participants in the intervention group required fewer additional invasive pleural procedures by 12 weeks (two [3%] of 60 vs 19 [34%] of 56, p<0·0001) Trial related adverse events rates were similar in both groups (46 [74%] of 62 vs 44 [71%] of 62, p=0·84). Three related serious adverse events were recorded, all occurring in the intervention group.</p><p><strong>Interpretation: </strong>The combination of medical thoracoscopy, poudrage, and IPC did not result in shorter hospital stay but was safe and resulted in similar dyspnoea control compared with standard care. For patients with symptomatic MPE undergoing med","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":" ","pages":""},"PeriodicalIF":32.8,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147322700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-23DOI: 10.1016/s2213-2600(26)00059-7
Bryant Furlow
{"title":"US EPA to roll back restrictions on upwind pollution","authors":"Bryant Furlow","doi":"10.1016/s2213-2600(26)00059-7","DOIUrl":"https://doi.org/10.1016/s2213-2600(26)00059-7","url":null,"abstract":"","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"45 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147278226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-16DOI: 10.1016/s2213-2600(25)00468-0
Joan B Soriano, Gregory G King, Christine R Jenkins
{"title":"The modified in Manila Medical Research Council dyspnoea scale","authors":"Joan B Soriano, Gregory G King, Christine R Jenkins","doi":"10.1016/s2213-2600(25)00468-0","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00468-0","url":null,"abstract":"","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"35 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146209681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-16DOI: 10.1016/s2213-2600(26)00015-9
Hans Kluge, Madhukar Pai
{"title":"Three reasons why the European region should worry about tuberculosis","authors":"Hans Kluge, Madhukar Pai","doi":"10.1016/s2213-2600(26)00015-9","DOIUrl":"https://doi.org/10.1016/s2213-2600(26)00015-9","url":null,"abstract":"","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"7 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146209680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：